Osage University Partners has contributed to an oversubscribed series C round for Cyteir, which was led by RA Capital.

Today's deal net contains news from PGDx, Notch Therapeutics, Quell Therapeutics, SpyBiotech, Vision Medicals, Future Meat Technologies, BusUp and Advanced Chemotherapy Technologies.

Cambridge and CRUK spinout Inivata has more than doubled its series C round to $60m following a $35m extension backed by IP Group.

GV and Novartis Venture Fund joined 6 Dimensions Capital in a round that brought Harvard’s oncology drug developer's overall funding to $160m.

Northpond and Deerfield have co-led a $75m series C round for Encodia, seemingly the first publicly disclosed funding for the WashU spinout.

Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.

The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.

University of Michigan and Virginia-founded Everactive has reached its series C target after three tranches.

Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.